Carla J. Pantoja

Carla J. Pantoja

Auto-generated profile, based on publicly available information

Carla J. Pantoja

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Open access
ASAlexander V. Sorokin
Alexander V. Sorokin
HAHildur Arnardottir
Hildur Arnardottir
MSMaryia Svirydava
Maryia Svirydava
QNQimin Ng
Qimin Ng
YBYvonne Baumer
Yvonne Baumer
NMNehal N. Mehta
Nehal N. Mehta
Persistent skin inflammation and impaired resolution are the main contributors to psoriasis and associated cardiometabolic complications. Omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are known to exert beneficial effects on inflammatory response and lipid function. However, a specific role of omega-3 PUFAs in psoriasis and accompanied pathologies are still a matter of debate. Here, we carried out a direct comparison between EPA and DHA 12 weeks diet intervention treatment of psoriasis-like skin inflammation in the K14-Rac1V12 mouse model. By utilizing sensitive techniques, we targeted EPA- and DHA-derived specialized pro-resolving lipid mediators and identified tightly connected signaling pathways by RNA sequencing. Treatment with experimental diets significantly decreased circulating pro-inflammatory cytokines and bioactive lipid mediators, altered psoriasis macrophage phenotypes and genes of lipid oxidation. The superficial role of these changes was related to DHA treatment and included increased levels of resolvin D5, protectin DX and maresin 2 in the skin. EPA treated mice had less pronounced effects but demonstrated a decreased skin accumulation of prostaglandin E2 and thromboxane B2. These results indicate that modulating psoriasis skin inflammation with the omega-3 PUFAs may have clinical significance and DHA treatment might be considered over EPA in this specific disease.

21 June 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ABAlexander R. Berg
Alexander R. Berg
CHChristin G. Hong
Christin G. Hong
MSMaryia Svirydava
Maryia Svirydava
HLHaiou Li
Haiou Li
PPPhilip M. Parel
Philip M. Parel
NMNehal N. Mehta
Nehal N. Mehta

3 November 2023 in JID Innovations
Verified
Journal Article
Open access
SLSundus S. Lateef
Sundus S. Lateef
GWGrace A Ward
Grace A Ward
HLHaiou Li
Haiou Li
CPCarla Pantoja
Carla Pantoja
EFElizabeth Florida
Elizabeth Florida
NMNehal N. Mehta
Nehal N. Mehta
Psoriasis (PSO) is a chronic and systemic inflammatory autoimmune disease associated with atherosclerosis and myocardial infarction. Given that atherosclerosis is both inflammation and immune driven, we sought to expand on known immune and inflammatory biomarkers in a PSO cohort. In this study, we focus on oxidized mtDNA (ox-mtDNA), a product of cells undergoing pyroptosis, including keratinocytes, which was quantified in patients with PSO and individuals without PSO by ELISA. Patients with PSO had significantly higher ox-mtDNA levels than healthy subjects (mean ± SD = 9246 ± 2518 pg/ml for patients with PSO vs 7382 ± 2506 pg/ml for those without; P = .006). Importantly, ox-mtDNA was positively associated with IL-17a (β = 0.25; P = .03) and low-density granulocytes (β = 0.37; P = .005) but negatively associated with high-density lipoprotein-cholesterol (β = −0.29; P = .006). After adjusting for traditional cardiovascular risk factors, we found that ox-mtDNA was associated with noncalcified coronary burden, which was measured by coronary computed tomography angiography (β = 0.19; P = .003). Biologic-naïve patients with PSO receiving anti–IL-17a therapy had a 14% decrease in ox-mtDNA (mean ± SD: 10540 ± 614 pg/ml at baseline to 9016 ± 477 pg/ml at 1 year; P = .016) and a 10% reduction in noncalcified coronary artery burden (mean ± SD: 1.06 ± 0.45 at baseline, reducing to 0.95 ± 0.35 at 1 year; P = .0037). In summary, levels of ox-mtDNA in PSO are associated with measures of coronary plaque formation, indicating that this biomarker may be an autoimmune-driven early atherosclerotic feature.